METUPUK will advocate with life science companies to increase the number of MBC trials to a level reflective of the proportion of MBC patients within the breast cancer population. Trials offer real potential to save and extend lives. We want this to be recognised and participation encouraged.
METUPUK will communicate with life science companies to influence ratios of trial funding to a level proportionate of MBC patients within the breast cancer population.
METUPUK will monitor to what extent the life science companies clinical trials and treatments align with Cancer Outcomes and Services Dataset (COSD) Data and outcomes. Non-alignment will be challenged.
METUPUK will work to make breast cancer trials more easier to access for MBC patients.
METUPUK will encourage and promote the working collaboration of breast cancer charities to provide an equitable and improved trial system for everyone diagnosed with MBC. We will encourage the creation of a universal trial access patient portal.
METUPUK will lobby regulatory authorities to significantly hasten the drug approval process for all new MBC drug treatments.
METUPUK will encourage and promote the working collaboration of key stakeholders (i.e., NICE, NHS and pharmaceutical companies) to co-operate meaningfully to reduce the timescales for treatment access
METUPUK will work with stakeholders to secure broad patient access to new innovative treatment regimes.
METUPUK will encourage and promote the working collaboration of key stakeholders to ensure swift access to new, innovative treatments.
METUPUK will work to maximise the application of technological advances to improve collation and analysis of specific datasets for MBC. We will encourage medical decision-makers to use the information to better inform treatment decisions.
METUPUK will work collaboratively with key stakeholders to guarantee revolutionary new technologies are implemented to improve medical decisions for patients.